glimepiride has been researched along with dapagliflozin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Washburn, WN | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
| Elze, M; Hruba, V; Langkilde, AM; Parikh, S; Strojek, K; Yoon, KH | 2 |
| Del Prato, S; Nauck, M | 1 |
| Geissel, W | 1 |
| Liu, S; Mir, MU; Shao, H; Shi, L; Shi, Q; Zawadzki, NK; Zhai, S; Zou, D | 1 |
| Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y | 1 |
| Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D | 1 |
| Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA | 1 |
| Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F | 1 |
| Alexander, GC; Heyward, J; Mansour, O; Olson, L; Singh, S | 1 |
| Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y | 1 |
| Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH | 1 |
| El-Gharbawy, NM; Omran, GA; Werida, RH; Zekry, R | 1 |
2 review(s) available for glimepiride and dapagliflozin
| Article | Year |
|---|---|
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.
Topics: Amputation, Surgical; Benzhydryl Compounds; Glucosides; Humans; Lower Extremity; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Risk; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
9 trial(s) available for glimepiride and dapagliflozin
| Article | Year |
|---|---|
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2011 |
[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
[New attempt in a benefit evaluation].
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds | 2015 |
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections | 2018 |
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Interleukins; Treatment Outcome | 2023 |
4 other study(ies) available for glimepiride and dapagliflozin
| Article | Year |
|---|---|
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Humans; Hypoglycemic Agents; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2017 |
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Incidence; Kidney; Kidney Diseases; Male; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2017 |
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes Mellitus, Type 2; Drainage; Female; Fournier Gangrene; Glucosides; Hospitals, Rural; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Obesity; Perineum; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2021 |